Sensitization of chordoma cell lines to ionizing radiation

在实验室成立的第一年，我们已经获得了实验室运行所需的基本设备，并签署了从NCGC获得27种化合物所需的材料转让协议。根据我们与NCGC的协议，一次将不会有超过10种化合物被送到我们进行测试。NCGC还向我们提供了由他们的检测确定的参考50%致死剂量(LD50)值。使用细胞内ATP含量的定量分析(类似于NCGC最初使用的那些)，我们已经证实了我们有能力在提供前10种化合物的情况下，在LD50药物浓度的培养中复制大约50%的细胞毒性。最初的实验将辐射与ATP含量测定中的前10种药物相结合，表明这10种化合物中的一种可能在培养中起辐射增敏剂的作用。验证性分析正在进行中，将重点放在更标准化的定量分析上，如下所述。在建立电离辐射对脊索瘤细胞影响的可靠定量分析的其他努力中，我们初步发现，我们的原代脊索瘤细胞系UCH-1在稀疏培养时不形成集落。我们已经通过几种方式解决了这个问题。1.我们已经验证了基于ATP的检测方法，可以可靠地报告辐射增敏。2.我们已经确定了提高天然细胞系形成集落能力的生长条件，并处于优化这项技术的最后阶段。3.商业上可用的磷酸化伽马H_2AX保留分析正在优化，作为一种替代分析输出。4.还在使用并优化了每核伽马H_2AX保留分析。我们已经开始使用上述条件测试NCGC化合物的辐射增敏作用。

In the first year since establishing the laboratory, we have acquired the basic equipment required for laboratory operation, and executed the Materials Transfer Agreements necessary for us to obtain the 27 compounds from the NCGC. Per our agreement with NCGC, no more than 10 compounds will be sent to us at a time for testing. NCGC has also provided us with the reference 50% lethal dose (LD50) values, as determined by their assays. Using quantitative assays of intracellular ATP content (similar to those used initially by NCGC), we have confirmed our ability to replicate roughly 50% cytotoxicity at LD50 drug concentrations in culture with the first 10 compounds supplied. Initial experiments combining radiation with the first 10 drugs in ATP content assays have suggested that one of the 10 compounds may act as a radiosensitizer in culture. Confirmatory assays are ongoing and will focus on more standardized quantitative assays, as described below. In other efforts to establish reliable quantitative assays of the effects of ionizing radiation on chordoma cells, we initially found that our primary chordoma cell line UCH-1 does not form colonies when sparsely cultured. We have approached this problem in several ways. 1. We have validated ATP-based assays for reliable reporting of radiation sensitization. 2. We have identified growth conditions that improve the ability of the native cell lines to form colonies, and are in the final stages of optimizing this technique. 3. Commercially available phosphorylated gamma H2AX retention assays are being optimized as an alternative assay output. 4. Per nucleus gamma H2AX retention assays are also being used and have been optimized. We have begun testing the NCGC compounds for radiation sensitization using the conditions above.